Press release
August 6, 2026
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Ocugen, Inc. (OCGN)
Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter Granted Regenerative Medicine